Following SPA OK, Achaogen seeks $75M and listing as ‘AKAO’
By Jennifer Boggs
Monday, January 27, 2014
Set to start its Phase III trial for antibacterial candidate plazomicin this quarter, Achagoen Inc. filed for a $74.8 million initial public offering (IPO), which, along with anticipated funding from the Biomedical Advanced Research and Development Authority (BARDA), could take the firm through top-line data, expected in the first half of 2017.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.